Seoul St. Mary's Hospital Achieves 200 Cases of Antibody Treatment for Alzheimer's Disease
Establishing an Integrated Dementia Treatment System
Seoul St. Mary's Hospital has reached 200 cases of antibody treatment aimed at slowing the progression of Alzheimer's disease. The hospital explained that both the Department of Neurology and the Department of Psychiatry operate their own independent prescription systems, establishing an integrated care system for early-stage Alzheimer's patients that covers everything from diagnosis to medication and safety management.
As of May, Seoul St. Mary's Hospital announced on the 1st that it had achieved 200 cases of antibody treatment for Alzheimer's disease. Unlike conventional symptom-relief therapies, Alzheimer's antibody treatment is considered a disease-modifying therapy, as it removes amyloid beta protein, one of the causes of the disease, thereby slowing its progression.
Amyloid PET images showing amyloid accumulation. From left, normal brain, Alzheimer's disease. Seoul St. Mary's Hospital
View original imageAlzheimer's disease is a degenerative brain disorder in which abnormal accumulation of beta-amyloid and tau proteins in the brain damages nerve cells. In Korea, the introduction of antibody therapies targeting amyloid proteins into clinical practice began at the end of 2024, marking the start of a shift in the treatment paradigm.
Antibody therapies are known to be most effective in early-stage patients. Accurate diagnosis through amyloid positron emission tomography (PET) scans or cerebrospinal fluid testing is required before administration. In addition, biweekly intravenous infusions and regular brain magnetic resonance imaging (MRI) monitoring are necessary, making specialized medical staff and safety management systems essential.
Seoul St. Mary's Hospital operates a system in which the Departments of Neurology and Psychiatry cooperate with the Departments of Radiology, Nuclear Medicine, Laboratory Medicine, and Nursing, managing everything from amyloid PET diagnosis to medication administration and adverse reaction control.
Amyloid-related imaging abnormalities (ARIA), which can occur during treatment, may manifest as brain edema or microhemorrhages, making regular MRI monitoring important. Most cases are asymptomatic and manageable, but in rare instances, serious adverse reactions can occur, requiring monitoring by experienced medical professionals.
Dongwon Yang, Professor of Neurology at Seoul St. Mary's Hospital, said, "Dementia specialists are carefully selecting patients eligible for antibody therapy, and so far, serious side effects have been rare among Korean patients. It has also been confirmed that early-stage patients with lower initial levels of amyloid accumulation tend to respond more quickly to treatment."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Dongwoo Kang, Professor of Psychiatry, stated, "The introduction of anti-amyloid immunotherapies has marked a shift in Alzheimer's disease treatment from symptom management to targeting the pathology of the disease. Precision diagnosis and treatment strategies based on each patient's disease stage and biomarker status are crucial."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.